Open AccessEnhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F‐Benzoyl‐TN14003
Author(s) -
Abraham Michal,
Biyder Katia,
Begin Michal,
Wald Hanna,
Weiss Ido D.,
Galun Eithan,
Nagler Ar,
Peled Am
Publication year - 2007
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1634/stemcells.2007-0161
Subject(s) - cxcr4 , plerixafor , haematopoiesis , stem cell , progenitor cell , biology , cxcr4 antagonist , bone marrow , immunology , mobilization , cancer research , pharmacology , microbiology and biotechnology , immune system , chemokine , history , archaeology
An increase in the number of stem cells in blood following mobilization is required to enhance engraftment after high‐dose chemotherapy and improve transplantation outcome. Therefore, an approach that improves stem cell mobilization is essential. The interaction between CXCL12 and its receptor, CXCR4, is involved in the retention of stem cells in the bone marrow. Therefore, blocking CXCR4 may result in mobilization of hematopoietic progenitor and stem cells. We have found that the CXCR4 antagonist known as 4F‐benzoyl‐TN14003 (T‐140) can induce mobilization of hematopoietic stem cells and progenitors within a few hours post‐treatment in a dose‐dependent manner. Furthermore, although T‐140 can also increase the number of white blood cells (WBC) in blood, including monocytes, B cells, and T cells, it had no effect on mobilizing natural killer cells. T‐140 was found to efficiently synergize with granulocyte colony‐stimulating factor (G‐CSF) in its ability to mobilize WBC and progenitors, as well as to induce a 660‐fold increase in the number of erythroblasts in peripheral blood. Comparison between the CXCR4 antagonists T‐140 and AMD3100 showed that T‐140 with or without G‐CSF was significantly more potent in its ability to mobilize hematopoietic stem cells and progenitors into blood. These results demonstrate that different CXCR4 antagonists may have different therapeutic potentials. Disclosure of potential conflicts of interest is found at the end of this article.